€40 million was invested in a plant north off Moscow to produce 2 billion prescription drugs annually, Servier said in a statement late last week. The production is to start by the end of the year to reach an annual capacity of 4.5 billion tablets by 2011, Servier’s marketing director Yana Rostovtseva told Kommersant. “It will enable us to provide medicines not only for Russia but also for Eastern Europe,” she said. Hungarian pharmaceutical group Egis acted as a co-investor in the project. The plant is likely to help Servier increase its share in the Russia state-run drug program, according to David Melik-Guseinov, marketing research director at Pharmexport. The drug program, which provides pensioners and low-income families with free medicines, received 29 billion rubles last year. The budget for 2007 is some 35 billion rubles. Servier currently holds 4 percent in this market.
Foreign investors are also attracted by a booming growth of the Russian pharmaceutical market which rose 40% to $2 billion in the quarter ending in March, industry analysts say. (kommersant.com)
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
